BridgeBio Up 10% as Evercore ISI Has $40 Target – MarketWatch

By Josh Beckerman
BridgeBio Pharma Inc. shares increased 10% to $16.61 after Evercore ISI Group initiated coverage with an outperform rating and $40 price target.
Last week, SVB Securities maintained its outperform rating for the biopharmaceutical company focused on genetic diseases and cancers. SVB raised its target to $27 from $25.
Write to Josh Beckerman at
Many investors are underweight stocks and focused on what could go wrong. A possible Federal Reserve rate pause is something that could go right.
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client relationships and build investor experiences. Learn More.
Visit a quote page and your recently viewed tickers will be displayed here.


Leave a Reply

Your email address will not be published. Required fields are marked *

Back To Top